Loading data for CLRB — first visit, this takes a few seconds.
Cellectar Biosciences, Inc. (CLRB)
NasdaqCM: CLRB
· 即時價格 · USD
2.37
+0.02 (0.85%)
收盤價： Sep 11, 2026, 8:00 PM
2.31
+0.00%
盤後: 7:50 PM
股價、關鍵數字和最新消息，都在這一頁。
Cellectar Biosciences, Inc.（CLRB）股價、分析與資料
無可用資料
| 買價 | 1.73 |
| 市值 | 21.8M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -22.3M |
| 0.56 | |
| -2.17 | |
| n/a | |
| -1.21 | |
| P/B (ttm) | 0.64 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 12, 2026 |
| 賣價 | 3.07 |
| 成交量 | 26,570 |
| 20 日平均成交量 | 78,477 |
| 開盤價 | 2.37 |
| 前收盤價 | 2.35 |
| 當日區間 | 2.35 - 2.40 |
| 52 週範圍 | 2.20 - 6.52 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobu...
完整的公司簡介財報驚奇
Cellectar Biosciences 已於 Aug 13, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.57 低於預期 -0.05, 年增 83.19% 成長.
第 1 頁，共 2 頁